2482156E-29A8-4B6B-91BD-219EAC9229B5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.027595269382392
- age_years
- 54
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.506
- MYC_TARGETS_V2+0.496
- MYC_TARGETS_V1+0.441
- DNA_REPAIR+0.419
- OXIDATIVE_PHOSPHORYLATION+0.391
- UNFOLDED_PROTEIN_RESPONSE+0.334
- NOTCH_SIGNALING+0.306
- MTORC1_SIGNALING+0.301
- HEDGEHOG_SIGNALING+0.274
- WNT_BETA_CATENIN_SIGNALING+0.271
Top 10 suppressed
- ANGIOGENESIS-0.419
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.358
- APICAL_SURFACE-0.331
- IL6_JAK_STAT3_SIGNALING-0.310
- KRAS_SIGNALING_DN-0.303
- COAGULATION-0.295
- ALLOGRAFT_REJECTION-0.256
- SPERMATOGENESIS-0.247
- INFLAMMATORY_RESPONSE-0.233
- COMPLEMENT-0.218
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 83BB732E-132F-4677-B70D-5ADE69831226 | — | — | 0.940 |
| 2 | 2CF24C43-7C9D-4395-8C82-5A80361F9980 | — | — | 0.920 |
| 3 | 604B16D3-7546-4E8C-8443-F1447CC5DFD5 | — | — | 0.914 |
| 4 | 3A2D0D6F-66C3-48EE-9EA4-68668FF9B043 | — | — | 0.899 |
| 5 | 0093DCB6-A7C8-4841-8383-0671A71DDA71 | — | — | 0.896 |
| 6 | B9E0623C-E3AC-4B2B-983E-C2246AD0DB00 | — | — | 0.894 |
| 7 | 7A392761-6834-4B60-A49A-99D0D2AEC612 | — | — | 0.888 |
| 8 | 92A04345-2DCA-49F5-801F-926B59255925 | — | — | 0.885 |
| 9 | 09E07A63-5FD2-4E4F-9FD5-2BB204302232 | — | — | 0.884 |
| 10 | D0F8B6CA-5F3B-4B66-BCC5-72C17325DABF | — | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.506 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.496 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.441 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.419 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.391 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.334 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.306 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.301 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.274 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.271 | Inavolisib | — uncovered |
| PEROXISOME | 0.225 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.208 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.202 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.196 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.158 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.151 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.147 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.133 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.132 | Inavolisib | — uncovered |